These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 35230877)

  • 1. Intensive Voice Treatment (Lee Silverman Voice Treatment [LSVT LOUD]) for Children With Down Syndrome: Phase I Outcomes.
    Boliek CA; Halpern A; Hernandez K; Fox CM; Ramig L
    J Speech Lang Hear Res; 2022 Apr; 65(4):1228-1262. PubMed ID: 35230877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of an intensive voice treatment on articulatory function and speech intelligibility in children with motor speech disorders: A phase one study.
    Langlois C; Tucker BV; Sawatzky AN; Reed A; Boliek CA
    J Commun Disord; 2020; 86():106003. PubMed ID: 32505858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensive voice treatment (LSVT LOUD) for children with spastic cerebral palsy and dysarthria.
    Fox CM; Boliek CA
    J Speech Lang Hear Res; 2012 Jun; 55(3):930-45. PubMed ID: 22232407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic effects of intensive voice treatment (LSVT LOUD
    Boliek CA; Fox CM
    Int J Speech Lang Pathol; 2017 Dec; 19(6):601-615. PubMed ID: 27705010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lee Silverman voice treatment versus NHS speech and language therapy versus control for dysarthria in people with Parkinson's disease (PD COMM): pragmatic, UK based, multicentre, three arm, parallel group, unblinded, randomised controlled trial.
    Sackley CM; Rick C; Brady MC; Woolley R; Burton C; Patel S; Masterson-Algar P; Nicoll A; Smith CH; Jowett S; Ives N; Beaton G; Dickson S; Ottridge R; Sharp L; Nankervis H; Clarke CE;
    BMJ; 2024 Jul; 386():e078341. PubMed ID: 38986549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of intensive voice treatment (the Lee Silverman Voice Treatment [LSVT]) on ataxic dysarthria: a case study.
    Sapir S; Spielman J; Ramig LO; Hinds SL; Countryman S; Fox C; Story B
    Am J Speech Lang Pathol; 2003 Nov; 12(4):387-99. PubMed ID: 14658991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Intensive Voice Treatment (The Lee Silverman Voice Treatment [LSVT LOUD]) in Subjects With Multiple Sclerosis: A Pilot Study.
    Baldanzi C; Crispiatico V; Foresti S; Groppo E; Rovaris M; Cattaneo D; Vitali C
    J Voice; 2022 Jul; 36(4):585.e1-585.e13. PubMed ID: 32819780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of an extended version of the lee silverman voice treatment on voice and speech in Parkinson's disease.
    Spielman J; Ramig LO; Mahler L; Halpern A; Gavin WJ
    Am J Speech Lang Pathol; 2007 May; 16(2):95-107. PubMed ID: 17456888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Innovative technology for the assisted delivery of intensive voice treatment (LSVT®LOUD) for Parkinson disease.
    Halpern AE; Ramig LO; Matos CE; Petska-Cable JA; Spielman JL; Pogoda JM; Gilley PM; Sapir S; Bennett JK; McFarland DH
    Am J Speech Lang Pathol; 2012 Nov; 21(4):354-67. PubMed ID: 23071195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicentre, randomised controlled trial to compare the clinical and cost-effectiveness of Lee Silverman Voice Treatment versus standard NHS Speech and Language Therapy versus control in Parkinson's disease: a study protocol for a randomised controlled trial.
    Sackley CM; Rick C; Au P; Brady MC; Beaton G; Burton C; Caulfield M; Dickson S; Dowling F; Hughes M; Ives N; Jowett S; Masterson-Algar P; Nicoll A; Patel S; Smith CH; Woolley R; Clarke CE;
    Trials; 2020 May; 21(1):436. PubMed ID: 32460885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of Lee Silverman Voice Treatment (LSVT LOUD®) on voice, communication, and participation: Findings from a prospective, longitudinal study.
    Bryans LA; Palmer AD; Anderson S; Schindler J; Graville DJ
    J Commun Disord; 2021; 89():106031. PubMed ID: 33259945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensive voice treatment (the Lee Silverman Voice Treatment [LSVT
    Ertan E; Gürvit HI; Hanağası HH; Bilgiç B; Tunçer MA; Yılmaz C
    Logoped Phoniatr Vocol; 2022 Dec; 47(4):262-270. PubMed ID: 34287100
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of Lee Silverman Voice Treatment (LSVT LOUD®) on swallowing and cough in Parkinson's disease: A pilot study.
    Miles A; Jardine M; Johnston F; de Lisle M; Friary P; Allen J
    J Neurol Sci; 2017 Dec; 383():180-187. PubMed ID: 29246611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensive treatment of dysarthria in two adults with Down syndrome.
    Mahler LA; Jones HN
    Dev Neurorehabil; 2012; 15(1):44-53. PubMed ID: 22256834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of intensive voice treatment (the Lee Silverman Voice Treatment [LSVT]) on vowel articulation in dysarthric individuals with idiopathic Parkinson disease: acoustic and perceptual findings.
    Sapir S; Spielman JL; Ramig LO; Story BH; Fox C
    J Speech Lang Hear Res; 2007 Aug; 50(4):899-912. PubMed ID: 17675595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes of PD Check-In, a model for supported self-managed maintenance of speech in Parkinson's disease: A Phase 1 study.
    Finnimore A; Theodoros D; Rumbach AF
    Int J Lang Commun Disord; 2023 Mar; 58(2):241-255. PubMed ID: 36036751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telerehabilitation for Lee Silverman Voice Treatment (Tele-LSVT)-Loud on voice intensity and voice use in daily living in people with multiple sclerosis: A protocol for a feasibility and pilot randomized controlled study.
    Vitali C; Fusari G; Baldanzi C; Cacciatore DM; Crispiatico V; Carullo A; Rovaris M; Cattaneo D; Baglio F; Isernia S
    Digit Health; 2023; 9():20552076231218150. PubMed ID: 38074343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility and Acceptability of Lee Silverman Voice Treatment in Progressive Ataxias.
    Lowit A; Egan A; Hadjivassiliou M
    Cerebellum; 2020 Oct; 19(5):701-714. PubMed ID: 32588316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neural correlates of efficacy of voice therapy in Parkinson's disease identified by performance-correlation analysis.
    Narayana S; Fox PT; Zhang W; Franklin C; Robin DA; Vogel D; Ramig LO
    Hum Brain Mapp; 2010 Feb; 31(2):222-36. PubMed ID: 19639554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Lee Silverman Voice Treatment (LSVT®) speech therapy in progressive supranuclear palsy.
    Sale P; Castiglioni D; De Pandis MF; Torti M; Dall'armi V; Radicati FG; Stocchi F
    Eur J Phys Rehabil Med; 2015 Oct; 51(5):569-74. PubMed ID: 26138088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.